Me Therapeutics Holdings, Inc. · CSE:METX
Me Therapeutics — Investor Presentation (October 2025)
16 slides from Me Therapeutics's investor presentation, Oct 16, 2025
Slide 1: Reprograming the immune response against cancer
Reprograming the immune response against cancer October 16, 2025 METX: CSE | FSE:Q9T
Slide 2: Disclaimer and forward-looking statements
THIS PRESENTATION IS CONFIDENTIAL AND IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED, FURTHER DISTRIBUTED TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. This Presentation does not constitute an offer to sell or a solicitation of offers to buy
Slide 3: ME Therapeutics company overview
Myeloid Enhancement (ME) Therapeutics is a biotechnology company involved in the discovery and development of novel immuno- oncology therapeutics which reprogram the tumor microenvironment to fight cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells calle
Slide 4: Myeloid cell reprograming in vivo
MYELOID CELL REPROGRAMING IN VIVO • Myeloid cells (macrophages, myeloid derived suppressor cells) and Cancer associated fibroblasts (CAFs) are a major part of the tumor microenvironment (TME) • Myeloid cells and CAFs interfere with T cell activation by expressing inhibitory receptors and producing t
Slide 5: Unlocking small fraction of the market = significant revenue potential
Our drug candidates target the immune system and not the cancer directly so they may be used in several cancer types. (316,950 estimated cases in the U.S. in 2025)* Current Immuno-Oncology (IO) drugs (Keytruda, Opdivo) = ~ $190,000** (226,650 estimated cases in the U.S. in 2025)* (154,270 estimated
Slide 6: In vivo Pan-CAR program and therapeutic mRNA
• In vivo Pan- chimeric antigen receptor (CAR) program • CAR expression in myeloid and T cells • CD19/CD22 dual CAR for B cell leukemias • TME targeting CAR for solid tumors • Therapeutic mRNA to modulate tumor microenvironment (TME) • Stimulate immune cell recruitment and activation • Make cold tum
Slide 7: In vivo mRNA and CAR delivery to the TME
• In vivo therapeutic mRNA delivery to modulate tumor microenvironment (TME) • Creating ‘hot’ tumors • Targeted delivery of stimulatory proteins directly to the TME • Validated targets in development • Developing tumor-specific expression • Reduce systemic toxicity of key targets • In vivo chimeric
Slide 8: Partnered with NanoVation Therapeutics (NTx)
Partnered with NanoVation Therapeutics (NTx) • Long circulating Lipid Nanoparticle (LNP) addresses the key extrahepatic delivery challenge in mRNA delivery • Accumulates in the tumor microenvironment • Increases immune cell targeting (myeloid cells, T cells, or both) • NTx co-founded by world expert
Slide 9: CD19/CD22 in vivo Pan-CAR
CD19/CD22 in vivo Pan-CAR • CAR expression in both T cells and myeloid cells • dual antigen targeting approach for B-ALL and DLBCL • Novel CD22 nanobody binder being derisked in a Phase 1 clinical study • CD19 targeting already derisked clinically • Pan-CAR approach may lead to deeper B cell depleti
Slide 10: Therapeutic STING activating mRNA
Therapeutic STING activating mRNA • STING is a key target for creating a hot TME (increasing immune cell recruitment, stimulating antigen presentation, overcoming resistance to checkpoint) • Several small molecule STING activators in clinical trials • So far all have been unsuccessful due to toxicit
Slide 11: mRNA platform adds significant value to company
• mRNA platform adds significant value to company • Rapid design and testing of novel therapies based on cutting edge science • Proprietary mRNA design allows for targeted expression of protein of interest to modulate cancer or autoimmune conditions • Lower off-target effects and potentially greater
Slide 12: Blocking G-CSF overcomes resistance to VEGF therapies
• Blocking G-CSF reduces myeloid suppressor cells, increases T cells, and overcomes resistance to VEGF therapies • High affinity neutralizing antibody discovered and tested • Non-human primate studies completed demonstrating good pharmacology without observable toxicity (neutropenia) • Cell line dev
Slide 13: Upcoming milestones and 2026 plans
• In vivo Pan-CAR proof of concept studies 2026 • Initiate non-human primate (NHP) studies in late 2025/early 2026 • Non-GLP toxicology early 2026 • Potential IND late 2026 • Therapeutic mRNA program • In vivo mouse efficacy studies late 2025/ early 2026 • NHP toxicology mid-2026 • Potential IND lat
Slide 14: Management and directors
| PhD, CEO, Director & Founder | PhD, Director • Former director of preclinical research • Honorary Assistant Professor at University at Qu Biologics of British Columbia • Industry and academic expertise in cancer, • Expertise in lymphocyte biology, autoimmunity and inflammation inflammation, and ca
Slide 15: Capitalization and recent news
October 16, 2025 – ME Therapeutics granted licence for CD22 nanobody asset to expand next-gen in vivo CAR cell therapy Share Price (Oct 8, 2025) $4.00 program Shares outstanding 29,589,438 October 10, 2025 – ME Therapeutics added to CSE25 Index Shares reserved for 7,908,890 issuance September 26, 20
Slide 16: Thank You
Chief Executive Officer Address 2665 East Mall Room 249 Vancouver, British Columbia , Canada V6T 1Z4 Thank You Contact Info Email: salim@metherapeutics.com Website metherapeutics.com
ME Therapeutics Holdings — Investor Presentation (October 2025) on 6ix